Cargando…

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

BACKGROUND: Elderly patients with atrial fibrillation are at higher risk of both ischemic and bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE AF‐TIMI 48 trial, we evaluate clinical outcomes with edoxaban versus warfarin according to age. METHODS AND RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Eri Toda, Giugliano, Robert P., Ruff, Christian T., Koretsune, Yukihiro, Yamashita, Takeshi, Kiss, Robert Gabor, Nordio, Francesco, Murphy, Sabina A., Kimura, Tetsuya, Jin, James, Lanz, Hans, Mercuri, Michele, Braunwald, Eugene, Antman, Elliott M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889207/ https://www.ncbi.nlm.nih.gov/pubmed/27207971 http://dx.doi.org/10.1161/JAHA.116.003432

Ejemplares similares

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
por: Fanola, Christina L., et al.
Publicado: (2018)

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2016)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF‐TIMI 48 Trial
por: Eisen, Alon, et al.
Publicado: (2017)

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
por: Wang, Kaijun, et al.
Publicado: (2017)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
por: Yamashita, Takeshi, et al.
Publicado: (2020)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program
por: Chao, Tze-Fan, et al.
Publicado: (2023)

Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial
por: Wilkinson, Chris, et al.
Publicado: (2020)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
por: Murphy, Sabina A., et al.
Publicado: (2008)

The TIMI Study Group’s Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-
por: Toda Kato, Eri, et al.
Publicado: (2021)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
por: Chen, Cathy, et al.
Publicado: (2023)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
por: Ansell, Jack E., et al.
Publicado: (2017)

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial
por: Bergmark, Brian A., et al.
Publicado: (2021)

Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial
por: Akashi, Shintaro, et al.
Publicado: (2022)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Corrigendum to: Edoxaban in AF patients with PCI by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Publicado: (2020)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
por: Santamaria, Amparo, et al.
Publicado: (2023)

Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study
por: de Vries, T. A. C., et al.
Publicado: (2021)

Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry
por: Boriani, Giuseppe, et al.
Publicado: (2021)

Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial
por: Yoshida, Tetsuro, et al.
Publicado: (2022)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
por: Dellborg, Mikael, et al.
Publicado: (2019)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1uugfp4rgvig7dvogsm207hr4b